Polymer ± drug conjugates derived from copolymers of N-(2-hydroxypropyl)-methacrylamide (HPMA) can be prepared from a copolymer precursor such as 3 (Scheme 1). [1] This methodology has been used for the development of conjugate 4 which is currently undergoing Phase II trials in the UK for the treatment of cancer. [2] To exploit more widely the biological advantages of large molecule therapeutics [1, 3a] and to examine more thoroughly how structure, molecular weight, [4] and solution properties correlate with biological profile [3] it is essential to develop preclinical conjugates that have 1) narrow molecular weight main transition at 531 nm and e 40 000 for the Q-like transition at 830 nm were recorded.[29] a) Crystallographic parameters for 6 (dark prisms grown from vapor diffusion of CH 2 Cl 2 and hexanes): orthorhombic, space group Pbcn, a 9.0295(2), b 17.1213(4), c 24.7737(6) , Z 4, R1 0.0365, wR2 0.0612, V 3829.9 3 . The data were collected on a Nonius Kappa CCD diffractometer using a graphite monochromator with Mo Ka radiation (l 0.71073 ) at À 150 8C using a Oxford Cryostream low temperature device. The structure was refined by fullmatrix least-squares on F 2 to 0.0612, with R(F) equal to 0.0242 and a GOF 1.009. The complex lies on a crystallographic twofold rotation axis at 0,y, 1 4. The twofold axis passes through the uranium atom and bisects the bipyrrole and the tetrapyrrole moieties. b) The crystallographic parameters for [Et 3 NH][7] (red-green dichromic rods, of dimension 0.08 Â 0.08 Â 0.12 mm 3 , were grown from vapor diffusion of CH 2 Cl 2 and hexanes): monoclinic, space group P2 1 /c, a 15.099 (2), b 22.742(3), c 14.353(1) , b 110.857(4)8, V 4606(1) 3 , Z 4, 1 calcd 1.501 mg m À3 . The data were collected at 203 K on a Bruker P4/ [*] Prof.